AgingResearch.News
Alzheimer's & Dementia

Dementia progression with GLP-1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target-trial emulation study

By Meir Schechter, Dvora Rywka Sehtman-Shachar, Alisa Fishkin, Show 5 more authorsGenya Aharon-Hananel
Figure 1. Incidence of dementia or AD in people with MCI and T2D without dementia initiating GLP‐1 RAs compared with DPP4i.
Open the figure at full size
Figure 1. Incidence of dementia or AD in people with MCI and T2D without dementia initiating GLP‐1 RAs compared with DPP4i.Incidence of dementia or AD in people with MCI and T2D without dementia initiating GLP‐1 RAs compared with DPP4i.Schechter et al.
Cohort study of 1,320 peopleInterventions

Declared ties to: Novo Nordisk, AstraZeneca, Eli Lilly and Company and 12 more

Paper

The paper

Meir Schechter, Dvora Rywka Sehtman-Shachar, Alisa Fishkin, Show 5 more authorsGenya Aharon-Hananel

Reichman University; Hebrew University of Jerusalem

Alzheimer's & Dementia, 20 Sep 2026

doi.org/10.1002/trc2.70315PubMed 42769274

More on GLP-1 receptor agonists